
    
      This study was terminated on 19 April 2009 due to unfavorable risk benefit ratio of Bosutinib
      in combination with Letrozole including one confirmed Hy's law case. 37.5% of patients had
      treatment related liver events with the majority of severe events resulting in permanent
      study treatment discontinuation.
    
  